Repare Therapeutics Inc. – NASDAQ:RPTX

Add to watchlist

$1.52

+0.22

+17.83%

Market closed

Open in about 9 hours

-62.93%

month

-62.93%

quarter

-81.55%

year

Market Cap	56.11M
Enterprise value	214.82M

P/E	-12.39
EV/Sales	1.89
EV/EBITDA	-23.29
Price/Sales	3.24
Price/Book	1.31
PEG ratio	-0.16
EPS	-1.09

Revenue	97.85M
EBITDA	-68.71M
Income	-45.69M
Revenue Q/Q	822.93%
Revenue Y/Y	-28.62%

Profit margin	-25.56%
Oper. margin	-17.42%
Gross margin	0.6%
EBIT margin	-17.42%
EBITDA margin	-70.22%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Repare Therapeutics Inc. (NASDAQ:RPTX): Profit margin
Jun 2023	30.24M	-11.94M	-39.49%
Sep 2023	2.15M	-18.87M	-874.43%
Dec 2023	13.04M	-28.03M	-214.84%
Mar 2024	52.40M	13.16M	25.12%

Repare Therapeutics Financials Estimate

Q Y

Repare Therapeutics Inc. (NASDAQ:RPTX): Analyst Estimates
Mar 2024	52.40M	13.16M	25.12%
Sep 2025	4.7M	-38.76M	-824.85%
Oct 2025	3.35M	-42.92M	-1280.73%
Dec 2025	3.35M	-45.12M	-1346.41%

Analysts Price target
Financials & Ratios estimates

Repare Therapeutics Inc. (NASDAQ:RPTX): Earnings per share (EPS)
2023-11-09	-0.86	-0.45
2024-02-28	-0.56	-0.67
2024-05-07	0.016	0.3

Repare Therapeutics Inc. (NASDAQ:RPTX): Debt to assets
Jun 2023	301588000	56.17M	18.63%
Sep 2023	286407000	53.03M	18.52%
Dec 2023	253901000	41.81M	16.47%
Mar 2024	263084000	31.13M	11.83%

Repare Therapeutics Inc. (NASDAQ:RPTX): Cash Flow
Jun 2023	-34.34M	28.35M	40K
Sep 2023	-32.87M	24.49M	284K
Dec 2023	-28.15M	31.87M	105K
Mar 2024	11.93M	-20.31M	375K

Repare Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Repare Therapeutics Inc. (NASDAQ:RPTX): Employee count
Aug 2023	180
Sep 2023	180
Oct 2023	180
Nov 2023	180
Dec 2023	180
Jan 2024	180
Feb 2024	180
Mar 2024	179
Apr 2024	179
May 2024	179
Jun 2024	179
Jul 2024	179

Repare Therapeutics
Hedge Funds Holdings Q1 2023

31.09% -44.57%

of RPTX is owned by hedge funds

43 -35

hedge funds hold RPTX stock

13.03M -20.39M

shares is hold by hedge funds

RPTX hedge funds holdings changes

Repare Therapeutics
Insider Trading

Repare Therapeutics Inc. (NASDAQ:RPTX): Insider trades (number of shares)
Period	Buy	Sel
Jun 2023	0	10473
Nov 2023	2011010	0
Mar 2024	0	17700
Apr 2024	0	3990

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	1 Apr 2024	SEGAL LLOYD MITCHELL director, officer..	Common Shares	2,491	$4.63	$11,533
Sale	1 Apr 2024	FORTE STEVE officer: EVP, CHIEF FINANCIAL OFFICER officer: EVP, CHIEF FINANCIAL O..	Common Shares	789	$4.61	$3,637
Sale	1 Apr 2024	ZINDA MICHAEL officer: EVP, CHI..	Common Shares	410	$4.66	$1,911
Sale	1 Apr 2024	KOEHLER MARIA officer: EVP, CHI..	Common Shares	300	$4.66	$1,398
Sale	28 Mar 2024	SEGAL LLOYD MITCHELL director, officer..	Common Shares	2,650	$4.62	$12,243
Sale	28 Mar 2024	FORTE STEVE officer: EVP, CHIEF FINANCIAL OFFICER officer: EVP, CHIEF FINANCIAL O..	Common Shares	825	$4.62	$3,812
Sale	28 Mar 2024	ZINDA MICHAEL officer: EVP, CHI..	Common Shares	450	$4.64	$2,088
Sale	28 Mar 2024	KOEHLER MARIA officer: EVP, CHI..	Common Shares	500	$4.64	$2,320
Sale	27 Mar 2024	FORTE STEVE officer: EVP, CHIEF FINANCIAL OFFICER officer: EVP, CHIEF FINANCIAL O..	Common Shares	825	$4.62	$3,812
Sale	27 Mar 2024	ZINDA MICHAEL officer: EVP, CHI..	Common Shares	450	$4.62	$2,079

RPTX insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS Filling date: 20 Jan 2022 Issue date: 16 Jun 2022	20 Jan 2022	16 Jun 2022
Application	Application COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS Filling date: 30 Apr 2021 Issue date: 9 Sep 2021	30 Apr 2021	9 Sep 2021
Application	Application USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS Filling date: 11 Dec 2020 Issue date: 17 Jun 2021	11 Dec 2020	17 Jun 2021

Repare Therapeutics
Executives

Insider	Age	Compensation
Mr. Lloyd Mitchell Segal (1964) Pres, Chief Executive Officer & Director	61	$878,370
Dr. Maria Koehler M.D., Ph.D. (1957) Executive Vice President & Chief Medical Officer	68	$625,020
Dr. Michael Zinda Ph.D. (1971) Executive Vice President & Chief Scientific Officer	54	$585,850

Repare Therapeutics
Latest News

Friday, 13 December 2024
12:09	Why Is Repare Therapeutics Stock Trading Lower On Friday?	benzinga.com
Thursday, 12 December 2024
16:20	Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial	businesswire.com
Tuesday, 10 December 2024
16:05	Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial	businesswire.com
Tuesday, 12 November 2024
07:05	Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib	businesswire.com
Thursday, 7 November 2024
07:05	Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results	businesswire.com
Wednesday, 23 October 2024
06:05	Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial	businesswire.com
Tuesday, 15 October 2024
10:05	RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug	zacks.com
Monday, 14 October 2024
07:05	Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor	businesswire.com
Monday, 30 September 2024
16:05	Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting	businesswire.com
Monday, 23 September 2024
07:05	Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers	businesswire.com
Friday, 30 August 2024
18:13	Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data	seekingalpha.com
Wednesday, 28 August 2024
16:05	Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio	businesswire.com
Tuesday, 6 August 2024
18:51	Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates	zacks.com
Wednesday, 26 June 2024
10:30	Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI	businesswire.com
Wednesday, 12 June 2024
07:00	Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib	businesswire.com
Monday, 10 June 2024
07:05	Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial	businesswire.com
Thursday, 6 June 2024
11:01	Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag	zacks.com
Tuesday, 4 June 2024
16:05	Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer	businesswire.com
Monday, 3 June 2024
16:05	Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	businesswire.com
Wednesday, 29 May 2024
07:05	Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024	businesswire.com
Tuesday, 7 May 2024
16:05	Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results	businesswire.com
Tuesday, 30 April 2024
07:05	Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition	businesswire.com
07:05	Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition	businesswire.com
Friday, 26 April 2024
16:05	Repare Therapeutics Appoints Steven H. Stein, M.D.	businesswire.com
Thursday, 21 March 2024
10:00	Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	businesswire.com
Friday, 15 March 2024
14:35	Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	businesswire.com
Monday, 11 March 2024
20:00	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	prnewswire.com
Tuesday, 5 March 2024
12:15	Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - RPTX	accesswire.com
Sunday, 3 March 2024
10:15	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	prnewswire.com
Thursday, 29 February 2024
07:05	Repare Therapeutics to Participate in Two Upcoming Investor Conferences	Business Wire

Ideas & Opinions

Seeking Alpha 7 Nov 2023

Repare: Potential Of Camonsertib With Several Shots On Goal
Seeking Alpha 3 Oct 2023

Repare Therapeutics: A Compelling Bet On Synthetic Lethality
Seeking Alpha 6 Oct 2022

Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data
Seeking Alpha 7 Sep 2022

Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Seeking Alpha 27 Jun 2022

Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go

Frequently Asked Questions (FAQ)

What's the price of Repare Therapeutics stock today?

One share of Repare Therapeutics stock can currently be purchased for approximately $1.52.
When is Repare Therapeutics's next earnings date?

Unfortunately, Repare Therapeutics's (RPTX) next earnings date is currently unknown.
Does Repare Therapeutics pay dividends?

No, Repare Therapeutics does not pay dividends.
How much money does Repare Therapeutics make?

Repare Therapeutics has a market capitalization of 56.11M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 61.21% to 51.13M US dollars. Repare Therapeutics made a loss 93.8M US dollars in net income (profit) last year or $0.3 on an earnings per share basis.
What is Repare Therapeutics's stock symbol?

Repare Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "RPTX".
What is Repare Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Repare Therapeutics?

Shares of Repare Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Repare Therapeutics's key executives?
Repare Therapeutics's management team includes the following people:
- Mr. Lloyd Mitchell Segal Pres, Chief Executive Officer & Director(age: 61, pay: $878,370)
- Dr. Maria Koehler M.D., Ph.D. Executive Vice President & Chief Medical Officer(age: 68, pay: $625,020)
- Dr. Michael Zinda Ph.D. Executive Vice President & Chief Scientific Officer(age: 54, pay: $585,850)
How many employees does Repare Therapeutics have?

As Jul 2024, Repare Therapeutics employs 179 workers.
When Repare Therapeutics went public?

Repare Therapeutics Inc. is publicly traded company for more then 5 years since IPO on 19 Jun 2020.
What is Repare Therapeutics's official website?

The official website for Repare Therapeutics is reparerx.com.
Where are Repare Therapeutics's headquarters?

Repare Therapeutics is headquartered at 7210 Frederick-Banting, Montreal, QC.
How can i contact Repare Therapeutics?

Repare Therapeutics's mailing address is 7210 Frederick-Banting, Montreal, QC and company can be reached via phone at 857 412 7018.

Repare Therapeutics Inc.

reparerx.com

Exchange:

NASDAQ

Full time employees:

179

Industry:

Biotechnology

Sector:

Healthcare

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

857 412 7018

7210 Frederick-Banting
Montreal, QC H4S 2A1

CIK: 0001808158
ISIN: US7602731025
CUSIP: 760273102